财经快讯|神威药业:一季度未经核数师审阅管理账目内营业额11.18亿元,同比减少6.1%
神威药业5月6日在港交所公告,公司及其附属公司2024年一季度未经核数师审阅的管理账目内营业额达11.18亿元,较2023年同季度减少6.1%。分别是注射液产品的营业额减少17.0%至4.06亿元;软胶囊产品的营业额增加2.4%至1.72亿元;颗粒剂产品的营业额增加37.2%至1.99亿元;中药配方颗粒产品的营业额减少12.9%至2.83亿元;及其他剂型产品的营业额减少9.4%至0.58亿元。
Statement:
The content of this article does not represent the views of fxgecko website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!